{"id":511615,"date":"2025-03-04T00:00:00","date_gmt":"2025-03-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidwh0006-biopharma-polycystic-ovarian-syndrome-pcos-epidemiology-mature-markets\/"},"modified":"2026-04-15T23:11:52","modified_gmt":"2026-04-15T23:11:52","slug":"epidwh0006-biopharma-polycystic-ovarian-syndrome-pcos-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidwh0006-biopharma-polycystic-ovarian-syndrome-pcos-epidemiology-mature-markets\/","title":{"rendered":"Polycystic Ovarian Syndrome (PCOS) &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of polycystic ovarian syndrome (<abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr>\u00a0for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr>\u00a0forecast will answer the following questions:<\/p>\n<ul>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr>\u00a0over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts five <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr> patient populations, as follows:<\/p>\n<ul>\n<li>Total prevalent cases<\/li>\n<li>Diagnosed prevalent cases<\/li>\n<li>Total prevalent cases of <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr> with obesity<\/li>\n<li>Total prevalent cases of <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr> with infertility<\/li>\n<li>Total prevalent cases of <abbr title=\"polycystic ovarian syndrome\">PCOS<\/abbr> with hirsutism<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-511615","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/511615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/511615\/revisions"}],"predecessor-version":[{"id":511899,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/511615\/revisions\/511899"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=511615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}